Objective Drug delivery systems are a matter of intensive scientific investigation and technological developments. They are necessary since many active pharmaceutical ingredients to be employed in therapy, diagnostics or vaccination cause serious side effects when distributed non-specifically. Without a drug delivery system, the active pharmaceutical ingredients may accumulate in healthy and sensitive tissue, provoke adverse immune reactions, have poor solubility, low bioavailability and inefficient targeting.To meet these challenges, the key objectives of the proposed project are the development and testing of an innovative production technology for nanocapsules as a drug delivery system using centrifugation, colloidal and fluid mechanical techniques. These novel nanocapsules should be especially suited for proteins and other sensitive biomolecules which are vulnerable to degradation by existing encapsulation technologies. An immune protection consisting of a suitable polymer cover of the nanocapsules has to be developed to enable long circulation in human blood without provoking innate immune reactions by the complement, the coagulation and the phagocytic systems. Other than established polymer protection systems, the novel polymer protection should not be immunogenic to avoid accelerated blood clearance upon repeated administration. The nanocapsules have to prove to be sufficiently stable in human blood ex vivo. In vitro and in vivo tests in cancer models will be performed to compare drug efficiency, immune reactions and organ distribution of encapsulated and non encapsulated active pharmaceutical ingredients. Multidisciplinary research and innovation for nanomedicine is aimed for by collaboration in an intersectoral research team comprising mechanical and process engineering, pharmaceutical technology, immunology and cancer research. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsnatural scienceschemical sciencespolymer sciencesmedical and health sciencesbasic medicineimmunologymedical and health sciencesmedical biotechnologynanomedicinemedical and health sciencesclinical medicineoncology Programme(s) FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Topic(s) FP7-PEOPLE-2012-IAPP - Marie Curie Action: "Industry-Academia Partnerships and Pathways" Call for proposal FP7-PEOPLE-2012-IAPP See other projects for this call Funding Scheme MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP) Coordinator ABNOBA GMBH Address Hohenzollernstrasse 16 75177 Pforzheim Germany See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) projects.administrative_contact Gero Leneweit (Dr.) Links Contact the organisation Opens in new window Website Opens in new window EU contribution € 481 842,40 Participants (3) Sort alphabetically Sort by EU Contribution Expand all Collapse all UNIVERSITEIT UTRECHT Netherlands EU contribution € 464 451,69 Address Heidelberglaan 8 3584 CS Utrecht See on map Activity type Higher or Secondary Education Establishments projects.administrative_contact Martin De Geest (Mr.) Links Contact the organisation Opens in new window Website Opens in new window UPPSALA UNIVERSITET Sweden EU contribution € 272 463,21 Address Von kraemers alle 4 751 05 Uppsala See on map Activity type Higher or Secondary Education Establishments projects.administrative_contact Pirkko Boox (Mrs.) Links Contact the organisation Opens in new window Website Opens in new window KARLSRUHER INSTITUT FUER TECHNOLOGIE Germany EU contribution € 273 787,80 Address Kaiserstrasse 12 76131 Karlsruhe See on map Activity type Higher or Secondary Education Establishments projects.administrative_contact Nadja Hafendörfer (Mrs.) Links Contact the organisation Opens in new window Website Opens in new window
